“…Similar to abciximab and tirofiban, eptifibatide is a GPI that blocks the final common pathway of platelet aggregation by binding to platelet GP b/ a receptors, which bind to fibrinogen and other adhesive proteins that crosslink adjacent platelets 4,[33][34][35] . It also has dose-dependent antiplatelet, dethrombotic, and anti-inflammatory features [6][7][8][34][35][36] . Because they compete with fibrinogen in binding to the platelet GP b/ a receptor, high localized concentrations of the drug may enable the dissociation of bound fibrinogen and dissolve the formed thrombus 6,[36][37][38] .…”